Observational study of the effect of immunoadsorption (IA) in patients < 18 years of age with ME/CFS with evidence of autoantibodies
- Conditions
- G93.3Postviral fatigue syndrome
- Registration Number
- DRKS00032963
- Lead Sponsor
- Medizinische Klinik, Diako Flensburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patients aged 12 to <18 years with the clinical picture of ME/CFS diagnosed according to the Canadian Consensus Criteria (CCC) adapted for children.
Written informed consent from patients and legal guardians
Detection of autoantibodies (AAK) (adrenergic antibodies, ANA, antineuronal antibodies, or AAK to G protein-coupled receptors (GPCR) or others.
Planned immunoadsorption with the TheraSorb®-Ig omni column over 5 treatment days.
Exclusion Criteria
Lack of willingness to store pseudonymized disease data as part of the study.
Other medical conditions that do not allow the diagnosis to be secured (e.g., heart failure, pulmonary disease, major depression, cancer)
Acute infection
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method